GATAD2A

GATAD2A (p66α) is a core subunit of the Mi-2/NuRD chromatin-remodeling complex that couples DNA methylation reading to gene silencing by physically bridging the methyl-CpG-binding protein MBD2 to the CHD4/Mi-2 remodeler (PMID:21490301). It engages MBD2 through an anti-parallel heterodimeric coiled-coil whose specificity is set by complementary electrostatic surfaces, with comparable affinity for MBD2 and MBD3 (PMID:23239876); disrupting this coiled-coil relieves MBD2-mediated globin gene silencing (PMID:21490301). In parallel, the conserved CR2 region of GATAD2A contacts histone tails, an interaction abolished by point mutation and antagonized by histone acetylation, that is required for MBD2-dependent repression and proper subnuclear localization (PMID:16415179). GATAD2A and its paralog GATAD2B form mutually exclusive homodimers that define distinct NuRD subcomplexes, and the ZMYND8 MYND domain directly recognizes PPPLΦ/proline-rich motifs in GATAD2A's central region to recruit NuRD to chromatin—both to poly(ADP-ribose)-marked DNA damage sites to promote homologous recombination (PMID:27732854) and to repress specific transcriptional targets (PMID:41999894). Functionally, GATAD2A defines a Gatad2a-Chd4-Mbd3 axis within Mbd3/NuRD that suppresses the pluripotency circuitry during reprogramming and differentiation (PMID:30122475), and it is essential for early mouse embryonic development (PMID:17565372). Beyond NuRD, GATAD2A acts as a p53 co-activator, binding the p53 DNA-binding domain via CR2 to promote p53 occupancy at target promoters (PMID:34944103). In erythroid progenitors GATAD2A haploinsufficiency impairs CHD4 recruitment to MBD2-NuRD and reactivates fetal hemoglobin, ameliorating β-thalassemia (PMID:33997955), and de novo dominant missense variants that disrupt GATAD2A binding to CHD3/CHD4/CHD5 cause a NuRD-related neurodevelopmental disorder (PMID:37181331).

1. 2006 High

   Established that GATAD2A is not merely a scaffold but directly reads chromatin, linking MBD2 to histone tails through its CR2 region to enable repression.

   Evidence In vitro histone-tail binding, point mutagenesis, Co-IP, knockdown, and subnuclear localization microscopy

   PMID:16415179

   Open questions at the time

   • Does not resolve which specific histone residues or modification states beyond acetylation govern binding
   • Structural basis of the CR2-histone interaction not determined
2. 2007 Medium

   Showed GATAD2A is physiologically essential, establishing organismal relevance for methylated-DNA-dependent silencing.

   Evidence Gatad2a knockout mouse with embryonic lethality and expression profiling

   PMID:17565372

   Open questions at the time

   • Causative molecular lesion underlying lethality inferred, not directly demonstrated
   • Tissue-specific requirements not separated from global silencing role
3. 2011 High

   Identified the GATAD2A coiled-coil as the bridge that recruits CHD4 to MBD2-NuRD, defining a targetable node controlling globin silencing.

   Evidence Coiled-coil structural/biophysical characterization with dominant-negative peptide and globin silencing assays in erythroid cells

   PMID:21490301

   Open questions at the time

   • Did not establish stoichiometry of CHD4 within the assembled complex
   • Generality beyond globin loci not tested
4. 2012 High

   Resolved how GATAD2A selects its partner, defining the antiparallel heterodimer architecture and affinity hierarchy across MBD2/MBD3 family members.

   Evidence Analytical ultracentrifugation, circular dichroism, and biophysical binding with charge-altering mutants

   PMID:23239876

   Open questions at the time

   • In vitro peptide system does not capture full-complex context
   • Functional consequence of MBD2 vs MBD3 preference in cells not addressed
5. 2016 High

   Connected GATAD2A to genome maintenance, showing ZMYND8-mediated recruitment of NuRD to DNA damage and defining paralog-exclusive subcomplexes.

   Evidence Co-IP, genome-wide ChIP-seq, ZMYND8 depletion, live-cell DNA damage imaging, and MYND domain mapping

   PMID:27732854

   Open questions at the time

   • Mechanism by which NuRD promotes homologous recombination at the chromatin level not fully resolved
   • Whether GATAD2A and GATAD2B subcomplexes have distinct functional outputs not established
6. 2018 High

   Placed GATAD2A in the pluripotency-suppressing arm of Mbd3/NuRD, defining a Gatad2a-Chd4-Mbd3 axis required to block naive pluripotency.

   Evidence Gatad2a knockout in mouse cells with iPSC reprogramming assays and complex assembly analysis

   PMID:30122475

   Open questions at the time

   • Direct target loci of the axis during reprogramming not enumerated
   • Relationship to GATAD2A's DNA-damage role not integrated
7. 2021 Medium

   Revealed a NuRD-independent activity, with GATAD2A acting as a p53 co-activator via CR2 binding to the p53 DNA-binding domain.

   Evidence Co-IP, CR2 domain mapping, ChIP, and p53 target expression upon depletion/overexpression in breast cancer cells

   PMID:34944103

   Open questions at the time

   • Single-lab evidence not independently replicated
   • How GATAD2A reconciles repressive NuRD and activating p53 roles is unexplained
8. 2021 Medium

   Demonstrated therapeutic relevance: GATAD2A haploinsufficiency reactivates fetal hemoglobin by impairing CHD4 recruitment to MBD2-NuRD.

   Evidence Patient sequencing, CRISPR knockout in HUDEP-2/CD34+ progenitors, HbF quantification, and NuRD Co-IP

   PMID:33997955

   Open questions at the time

   • Single-lab functional data
   • Dose-response of GATAD2A levels on HbF not fully mapped
9. 2023 Medium

   Linked GATAD2A directly to human disease, showing de novo missense variants disrupt binding to CHD3/CHD4/CHD5 and cause a NuRDopathy.

   Evidence De novo variant identification in affected individuals and interaction-disruption assays

   PMID:37181331

   Open questions at the time

   • Methods described at abstract level without full reconstitution detail
   • Genotype-phenotype correlation and cellular consequences not delineated
10. 2026 High

    Provided the structural basis for ZMYND8 recognition of GATAD2A and showed this recruitment drives transcriptional repression of a specific lncRNA target.

    Evidence Crystal structure of the ZMYND8 coiled-coil MYND domain, ChIP, binding assays with GATAD2A proline-rich motifs, and structure-function mutagenesis

    PMID:41999894

    Open questions at the time

    • Breadth of ZMYND8-GATAD2A-regulated loci beyond MAPT213 not defined
    • Relationship to the DNA-damage recruitment role not unified

• How GATAD2A's distinct roles—NuRD-dependent repression, p53 co-activation, DNA-damage recruitment, and developmental silencing—are partitioned and regulated within a cell remains unresolved.
• No model integrating repressive NuRD and activating p53 functions
• Determinants selecting GATAD2A vs GATAD2B subcomplexes for specific tasks unknown
• Genome-wide map of direct GATAD2A targets across contexts incomplete